KEYNOTE-811 Trial of Pembrolizumab Combo Improves PFS in HER2+ Gastric/GEJ Cancer
October 20th 2023The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.
Read More
Improved pCR in Gastric/GEJ Cancer with Durvalumab/Chemo
October 20th 2023The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.
Read More
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC
October 20th 2023Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.
Read More
Improved PFS in Advanced Ovarian Cancer With Senaparib vs Placebo
October 20th 2023The phase 3 FLAMES trial results demonstrated an improvement in progression-free survival with senaparib monotherapy vs placebo, regardless of patient subgroup, in patients with newly diagnosed, advanced ovarian cancer.
Read More
Adjuvant Abemaciclib/ET Shows Sustainable Efficacy in HR+, HER2- Early Breast Cancer
October 20th 2023Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.
Read More
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma
September 13th 2022Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
Read More
Belzutifan/Cabozantinib Combo is Well Tolerated in Treatment-Naïve Advanced Clear Cell RCC
September 12th 2022The combination of belzutifan and cabozantinib was well tolerated in patients with treatment-naïve advanced clear cell renal cell carcinoma, according to findings presented at the 2022 ESMO Congress.
Read More
KEYNOTE-522 Trial of Pembrolizumab Does Not Negatively Affect HRQOL Outcomes in TNBC
September 12th 2022Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.
Read More
Pembrolizumab and Olaparib Combo Did Not Significantly Improve PFS and OS in mCRPC
September 12th 2022No statistically significant improvement in radiographic progression-free survival and overall survival was seen with pembrolizumab plus olaparib in metastatic castration-resistant prostate cancer.
Read More
2-Year ADT Plus Radiotherapy Following Surgery Improves MFS in Prostate Cancer
September 12th 2022The addition of 2 years of androgen-deprivation therapy to radiotherapy after radical prostatectomy improved metastasis-free survival and time to salvage therapy in patients with prostate cancer.
Read More